By Ranjeet Patil, Segment Head, Vaccines and Viral Therapies and Mochao Zhao, Global Product Manager, Single-use Membrane Chromatography
Viruses and their components are used in a variety of therapeutic modalities including vaccines and viral particles to create a protective immune response, gene therapies for corrective protein expression and oncolytic applications to target tumor cells. Regardless of the intended use, the viruses must be produced via a robust and cost‑efficient process. Unlike monoclonal antibodies (mAbs) for which production processes are highly industrialized and well‑characterized, the diversity of viruses and processes used for growth have precluded development of a similar templated approach which would help drive cost and production efficiencies.
This white paper provides an overview of the challenges presented by current approaches to virus production and the opportunities to develop a platform approach that can work across different viral modalities and accelerate process development. A series of case studies highlighting the application of downstream process intensification for production of viral vectors, oncolytic viruses and inactivated viral vaccines is provided.